secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-09-10T01:55:18+00:00
Accession:  0001935979-26-000077
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA partial clinical hold on BHV-7000 pauses new enrollment; dosing continues
-----------------------------------------------------------------------------

- FDA issued partial clinical hold letter Sept 4, 2026, pausing new patient enrollment pending nonclinical metabolite data.
- Dosing continues for >600 already randomized patients; BHV7000-303 fully enrolled, topline on track for H2 2026.
- BHV7000-302 new enrollment paused; open-label extension continues dosing; global sites voluntarily paused outside U.S.
- Over 1,200 participants dosed to date; metabolite findings may be rodent-specific and of uncertain human relevance.
- Aug 26, 2026 license agreement with SK Biopharmaceuticals for Kv7 platform incl. BHV-7000; HSR submission pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/0001935979-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer